PubMed · 2020 · 22 citations · 28 references
Open access
MedicineOncologyPharmacologyInflammationInnate ImmunityMolecular OncologyCancer Cell SignalingCancer Molecular PathologyInflammation-associated CarcinogenesisInflammatory SignalingSquamous Cell CarcinomaToll-like ReceptorsCetuximab TherapyEgfr InhibitionInflammation-driven Tumor ProgressionNf-κb SignalingToll-like Receptor SignalingToll-like Receptor Signaling PathwaysToll-like Receptors In CancerTumor-associated Inflammation
. Out study delineates a crosstalk between EGFR and TLR4 pathways and identified TLR4 as a potential biomarker as well as a therapeutic target in overcoming the resistance to anti-EGFR therapy of HNSCC.
28
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Masahiro Yamamoto, Shintaro Sato, Hiroaki Hemmi et al. · Science · 2003 · 3.2K citations
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel, Manfred Dietel, Lukas C. Heukamp et al. · Modern Pathology · 2016 · 350 citations · Full text
Medicine, Cell Biology, Oncology +10